ArticleExperimental and therapeutic medicine2026
Postoperative hypofractionated proton beam therapy to control recurrent paraganglioma at the jugular foramen: A case report.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paragangliomas (PGLs) are rare neuroendocrine tumors with malignant potential that may prove challenging to manage. Those arising at the jugular foramen are particularly problematic, especially if recurring after primary surgical treatment. Long-term follow-up is required, and effective treatment options for such recurrences are needed. The present study chronicles a recurring PGL of the jugular foramen that emerged after two surgeries. Alternative therapeutic strategies were accordingly pursued. This account of the related clinical course includes a discussion of the associated literature, focusing on the role of proton beam therapy (PBT) in PGL management and its benefits. The patient under treatment received hypofractionated PBT, utilizing intensity-modulated proton therapy/pencil-beam scanning techniques. The prescribed dose was 40 Gy in 15 fractions [equivalent dose in 2-gy fractions (EQD2), 42.09 Gy, assuming α/β=10) delivered to the gross tumor volume (GTV). Simultaneous integrated boosts to two inner subvolumes [GTV reduced by 2-mm margin, 50 Gy/15 fractions (EQD2, 55.49 Gy); and GTV reduced by 3-mm margin, 60 Gy/15 fractions (EQD2, 70.00 Gy)] took place as well. This process ensured precise radiation dosing, while adhering to strict dose constraints for adjacent critical structures. Hence, a quicker therapeutic response (aligned with that of stereotactic radiotherapy principles) was tenable, aiming for both tumor control and clinical improvement. Long-term follow-up is imperative to assess outcome durability. The aforementioned events illustrate the potential utility of advanced PBT techniques (namely pencil-beam scanning, hypofractionated regimens) in managing PGL recurrences of this type, especially if surgical options are limited or carry substantial risks. PBT offers a precise therapeutic alternative, with tumor control capabilities that promise to preserve critical tissues near key locations at the base of the skull.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.